Page 1

( OptiScan ASX Announcement 30 July 2021 Imaging Limited ABN 81 077 771 987 APPENDIX 4C QUARTERLY ACTIVITIES & CASHFLOW REPORTS QUARTER ENDED 30 JUNE 2021 Melbourne , Australia , 30 July 2021 : Optiscan Imaging Limited ( ASX : OIL ) ( OptiScan or the Company ) , a leader in medical technology using confocal laser endomicroscopy , is pleased to release its Appendix 4C – Quarterly Cashflow report and business update for the quarter ended 30 June 2021 ( Quarter ) . All financial results are in Australian dollars and are unaudited . Highlights for the Quarter • • • • • ● Continued imaging patients as part of the University of Melbourne's Melbourne Dental School ( MDS ) trial to improve screening , diagnosis and treatment of oral cancer , with 58 imaging sets completed by the end of the Quarter . Substantial progress in preparing for the application for FDA approval for the InVivage ™ device's use in oral cancer screening and surgery in the United States : 。 Continued third party independent testing and conducted validation and verification activities with further testing requirements being met ; ○ Successfully completed the required fluorescein dosing study . Completed imaging of 20 patients for stage three of the Breast Cancer Surgical Margin Assessment Trial . Orders from Carl Zeiss Meditec AG ( CZM ) for the CONVIVO device of approximately $ 200k for use in neurosurgey . OptiScan's quality management system was independently audited and certified as in accordance with international standard ISO13485 . Certification is for 3 years . Appointment of Mr Robert Cooke as Non - executive Chair and Professor Camile Farah as a Non - executive Director . Total Cash outflows and operating outflows for the quarter were ( $ 1.02m ) . Total Cash inflows for the financial year were $ 7.92m and Cash outflows from Operating Activities were ( $ 2.1m ) for the 12 months to 30 June 2021 . Developments Post End of Quarter • Due to success in patient recruitment , the Breast Trial has been expanded to 40 patients and OptiScan has imaged 27 patients . • OptiScan recorded its first Australian sale of the FIVE2 ( ViewnVivo ) system to a leading Australian University as part of a Victorian Government medical technology initiative . • The University of Adelaide Dental School received ethics approval for its " Proof of Concept Study : A diagnostic tool to detect Oral Squamous Cell Carcinoma " which will utilise OptiScan's FIVE2 ( ViewnVivo ) system . OptiScan is now working with Australia's two highest ranked dental schools ( University of Melbourne ranked # 14 in the world and University of Adelaide ranked # 25 in the world ) . • OptiScan continues to strengthen its distribution network for its FIVE2 ( ViewnVivo ) system , with the recent addition of South Korea to its existing distribution network which encompasses North America , Eastern and Southern China and Taiwan . OptiScan has appointed Ms Karen Borg as a non - executive Director with recent appointments to the Board comprising Directors with diverse experience across healthcare , marketing , strategy and finance . Phone ( 613 ) 9538 3333 Website www.OptiScan.com PO Box 1066 , Mt Waverley MDC VIC 3149 Australia